N-Propionyl-Cysteaminylphenol-Magnetite Conjugate (NPrCAP/M) Is a Nanoparticle for the Targeted Growth Suppression of Melanoma Cells  by Sato, Makito et al.
N-Propionyl-Cysteaminylphenol-Magnetite
Conjugate (NPrCAP/M) Is a Nanoparticle
for the Targeted Growth Suppression
of Melanoma Cells
Makito Sato1, Toshiharu Yamashita1, Masae Ohkura1, Yasue Osai1, Akiko Sato1, Tomoaki Takada1,
Hidenobu Matsusaka1, Ichiro Ono1, Yasuaki Tamura2, Noriyuki Sato2, Yasushi Sasaki3, Akira Ito4,
Hiroyuki Honda5, Kazumasa Wakamatsu6, Shosuke Ito6 and Kowichi Jimbow1
A magnetite nanoparticle, NPrCAP/M, was produced for intracellular hyperthermia treatment of melanoma by
conjugating N-propionyl-cysteaminylphenol (NPrCAP) with magnetite and used for the study of selective
targeting and degradation of melanoma cells. NPrCAP/M, like NPrCAP, was integrated as a substrate in the
oxidative reaction by mushroom tyrosinase. Melanoma, but not non-melanoma, cells incorporated larger
amounts of iron than magnetite from NPrCAP/M. When mice bearing a B16F1 melanoma and a lymphoma on
opposite flanks were given NPrCAP/M, iron was observed only in B16F1 melanoma cells and iron particles
(NPrCAP/M) were identified within late-stage melanosomes by electron microscopy. When cells were treated
with NPrCAP/M or magnetite and heated to 431C by an external alternating magnetic field (AMF), melanoma
cells were degraded 1.7- to 5.4-fold more significantly by NPrCAP/M than by magnetite. Growth of transplanted
B16 melanoma was suppressed effectively by NPrCAP/M-mediated hyperthermia, suggesting a clinical
application of NPrCAP/M to lesional therapy for melanoma. Finally, melanoma cells treated with NPrCAP/M
plus AMF showed little sub-G1 fraction and no caspase 3 activation, suggesting that the NPrCAP/M-mediated
hyperthermia induced non-apoptotic cell death. These results suggest that NPrCAP/M may be useful in targeted
therapy for melanoma by inducing non-apoptotic cell death after appropriate heating by the AMF.
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INTRODUCTION
Although early lesions of primary melanoma are curable by
excision, successful treatment of metastatic melanoma has
been elusive thus far. The current systemic therapies have
little effect on the overall survival period or rate of advanced
melanoma (Balch et al., 2001). Because melanogenesis is
inherently toxic and uniquely expressed in melanocytic cells,
tyrosine analogs can be good candidates for melanoma-
specific targeting and therapy (Jimbow et al., 1993). To
develop melanocytotoxic compounds for rational chemo-
therapy for melanoma, N-acetyl-cysteaminylphenol and
N-propionyl-cysteaminylphenol (NPrCAP) were synthesized.
These compounds showed selective cytotoxicity against
melanoma cells in vivo and in vitro (Jimbow et al., 1984;
Miura et al., 1990; Alena et al., 1994; Tandon et al., 1998).
They have both cytostatic and cytocidal effects on melanoma
cells (Thomas et al., 1999), and induce apoptosis in follicular
melanocytes of mice (Minamitsuji et al., 1999). Thus, these
synthetic compounds would provide the basis for the
development of novel anti-melanoma agents.
Iron oxide and magnetite nanoparticles are becoming
versatile tools for medical imaging of lymph nodes and are
excellent candidates for hyperthermia induced by an external
alternating magnetic field (AMF) due to the loss of hysteresis
(Leary et al., 2006; van Vlerken and Amiji, 2006). Local
hyperthermia is induced in tumors by injecting magnetite
nanoparticles into the core of the solid tumor and AMF
irradiation results in shrinkage of animal tumors (Luderer
et al., 1983; Minamimura et al., 2000). Magnetite cationic
liposomes (MCL) have been generated for the selective
accumulation of magnetite nanoparticles in tumor tissues,
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and MCL-mediated hyperthermia has inhibited growth or
induced complete regression of various tumors in the
transplanted animals (Yanase et al., 1998; Ito et al., 2003;
Kawai et al., 2005). If the magnetite nanoparticle technology
is taken a step farther to achieve a selective delivery system to
tumors, guided hyperthermia could be achieved for treatment
of metastatic tumors.
Recently, we synthesized an MCL in which NPrCAP was
encapsulated within the liposomes, resulting in both
intracellular hyperthermia and cytotoxicity when injected
into animal melanoma (Ito et al., 2007). Here, we introduce
another magnetite nanoparticle, NPrCAP/M, to which
NPrCAP was superficially bound to enhance its targeting
activity to melanoma cells. The possible mechanisms of
NPrCAP/M-mediated hyperthermia against melanoma are
discussed.
RESULTS
Incorporation of N-(1-mercaptopropionyl)-4-S-
cysteaminylphenol (NPrCAP-SH) with magnetite
The degree of incorporation of NPrCAP-SH with magnetite was
determined by HCl hydrolysis of NPrCAP/M followed by HPLC
analysis of the 4-S-cysteaminylphenol (4-S-CAP) produced. We
measured 4-S-CAP as an index of the degree of NPrCAP-SH
incorporation as they share the same structural units. The results
indicated that the degree of incorporation of NPrCAP-SH with
magnetite was 405nmolmg1 magnetite. When B16F1 cells
were cultured in NPrCAP/M-containing medium, collected, and
exposed to the AMF generator, the temperature rose sharply
from 30 to 501C within 10minutes and decreased immediately
after the machine was switched off (Figure 1).
NPrCAP/M as substrate for tyrosinase
We examined whether NPrCAP/M could act as a substrate for
tyrosinase. 4-S-CAP itself was found to be a good substrate for
mushroom tyrosinase; tyrosinase oxidation of 4-S-CAP
(100 mM) in the presence of cysteine yielded 5-S-cysteami-
nyl-3-S0-cysteinylcatechol through ortho-quinone within
10minutes. HPLC showed that the reaction was almost
completed within 10minutes with half of the 4-S-CAP
remaining after 4.2minutes. At the same time, the expected
catechol derivative was produced at 85 mM (85% yield) at
10minutes. As NPrCAP/M has the same structural units as
4-S-CAP, it was expected to be a substrate for tyrosinase.
If this were the case, 5-S-cysteaminyl-3-S0-cysteinylcatechol
would be obtained by HCl hydrolysis of the cysteinylcatechol
derivative of NPrCAP/M produced after tyrosinase oxidation
of NPrCAP/M in the presence of cysteine. NPrCAP/M fell to
half of the initial concentration after 69minutes, and the
concentration of 5-S-cysteaminyl-3-S0-cysteinylcatechol
produced after 3 hours was 80 mM (80% yield) (Figure 2).
Thus, the ratio of 4-S-CAP to NPrCAP/M in the reaction
velocity on tyrosinase oxidation was 16. These results
indicate that NPrCAP/M served as a substrate for mushroom
tyrosinase.
Measurement of the magnetite incorporated into cells treated
with NPrCAP/M
To examine whether NPrCAP/M could be incorporated into
melanoma cells more preferentially than magnetite alone, we
compared amounts of iron molecules in cells after culture in
the NPrCAP/M- or magnetite-containing medium. To prevent
non-specific adsorption of the particles to the cells, culture
flasks were filled with NPrCAP/M-containing medium and
rotated. After cells were collected and lysed, the amount of
iron was measured. As shown in Figure 3, MM418, 70W,
B16F1, SK-mel-23, TXM18, AK-1, and 96E melanoma cells
incorporated large amounts of iron derived from NPrCAP/M
compared with that from magnetite alone. Primary human
melanocytes and non-pigmented SK-mel-24 and SK-mel-118
cells captured a relatively large amount of NPrCAP/M;
however, the amount was not significantly different from
that from magnetite treatment or almost the same as for
magnetite (Figure 3).
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Figure 1. Heat generation in cells treated with NPrCAP/M and irradiated by
AMF. 2 106 B16F1 cells were cultured in NPrCAP/M (5.0mg magnetite
equivalent)-containing medium for 30minutes, collected, and exposed to the
center of the coil of the AMF generator. The temperature at the center of the
cell pellets was measured using an optical fiber probe. A rapid increase and
decrease in temperature were observed in the cell pellet during AMF
irradiation.
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Figure 2. NPrCAP/M is incorporated into the tyrosinase oxidative reaction
in vitro. The concentrations of the substrate remaining as 4-S-CAP and the 5-
S-cysteaminyl-3-S0-cysteinylcatechol produced were measured by HPLC
analysis after hydrolysis with HCl. ~: 4-S-CAP, ’: NPrCAP/M, K: 5-S-
cysteaminyl-3-S0-cysteinylcatechol from 4-S-CAP, m: 5-S-cysteaminyl-3-S0-
cysteinylcatechol from NPrCAP/M.
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NPrCAP/M is delivered to transplanted B16F1 melanomas
We then tested whether NPrCAP/M could be delivered to
B16F1 melanoma tumors transplanted into syngeneic C57BL/
6 mice. In five sets of experiments, each of which consisted of
three to five mice, we transplanted a B16F1 melanoma onto
the left flank and an EG7 or RMA lymphoma onto the right
flank, and we injected NPrCAP/M or magnetite into the
intraperitoneal cavity. After being allowed to grow for 2
weeks, tumors were excised and examined for the presence
of iron (NPrCAP/M) by Berlin blue staining. Blue-stained cells
were detected in 11 of the 14 melanomas, but in none of the
14 lymphomas (Figure 4a and b, Table 1). Meanwhile, in the
B16F1- and EG7-bearing mice given magnetite, blue-stained
tumor cells were not detected in either the melanoma or
lymphoma tissues.
B16F1 melanomas were removed and examined for the
subcellular localization of iron particles by electron micro-
scopy. B16F1 cells in the NPrCAP/M-injected mice contained
iron particles within dense ellipsoidal organelles, correspond-
ing to late-stage melanosomes (data not shown). This
suggested that NPrCAP/M was finally delivered to the
melanogenesis system of the melanocytic cells.
Cytotoxic effects of magnetically mediated hyperthermia on
melanoma cells
Because melanoma cells preferentially take up NPrCAP/M, it
was expected that NPrCAP/M-treated melanoma cells would
be selectively degraded by the AMF irradiation. MM418, SK-
mel-23, B16F1, and TXM18 melanoma and H1229, HaCaT,
HeLa, and SaOS2 non-melanoma cells were cultured in the
NPrCAP/M- or magnetite-containing medium, collected, and
irradiated by AMF at 431C for 30minutes. Figure 5 shows the
results for NPrCAP/M- or magnetite-treated cells with or
without hyperthermia induced by AMF. All the melanoma
cells tested were degraded more significantly by NPrCAP/M
with AMF than by magnetite with AMF, with differences
ranging from 1.7-fold in SK-mel-23 to 5.4-fold in B16F1 cells
(Figure 5a), whereas non-melanoma cells were degraded
almost equally by NPrCAP/M and magnetite (Figure 5b). These
results suggested that NPrCAP/M could induce the death of
melanoma cells more selectively and significantly than that of
non-melanoma cells at the relatively low temperature of 431C.
Hyperthermia mediated by NPrCAP/M effectively suppresses
growth of mouse melanoma
To evaluate whether NPrCAP/M-mediated hyperthermia
could suppress melanoma in the mouse model, we treated
the subcutaneously transplanted B16F1 melanoma and
measured the volumes of tumors (Figure 6). As shown in
Figure 6a, B16F1 melanoma in mice treated by magnetite
injection followed by AMF irradiation and NPrCAP/M
injection followed by AMF irradiation resulted in statistically
significant suppression of tumor growth compared with the
untreated melanoma (Figure 6a and b). NPrCAP/M-mediated
hyperthermia seemed to suppress growth of the melanoma
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Figure 3. Uptake of magnetite nanoparticles into melanoma and
non-melanoma cells. 75 cm2 flasks containing growing cells were filled with
NPrCAP/M- or magnetite-containing medium and fixed on a slanted disc,
which was rotated slowly for 30minutes. Incorporated iron was measured by
the potassium thiocyanate method. Melanoma cell line names (MM418 to
96E) are written in gothic. Data and bars are mean±SD of three independent
experiments (*Po0.05).
Figure 4. Intraperitoneal NPrCAP/M nanoparticles were delivered to the
subcutaneously transplanted melanoma tumors. Mice bearing B16F1 and
lymphoma tumors received i.p. administration of NPrCAP/M and were
maintained for 14 days. Tumors were then removed and processed for
hematoxylin–eosin and Berlin blue staining. Iron-containing blue-stained
tumor cells were detected in the B16F1 tissues (a), but not in the EG7 (b) or
RMA lymphoma tissues. Data are for five or four independent mice, each.
Bars represent 50 mm (a, b).
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more than hyperthermia mediated by magnetite alone;
however, differences between the two groups were not
statistically significant.
Non-apoptotic cell death is induced by NPrCAP-mediated
intracellular hyperthermia
Cellular DNA was prepared after cells had been cultured in
the NPrCAP/M-containing medium followed by AMF at 431C
and subjected to analysis by flow cytometry. B16F1 and SK-
mel-23 cells infected with a recombinant adenovirus expres-
sing Ad-p630 showed evident sub-G1 fractions, whereas cells
subjected to NPrCAP/M-mediated hyperthermia contained
little sub-G1 DNA (Figure 7). Levels of caspases 3, 8, and 9 in
B16F1 and SK-mel-23 cells after NPrCAP/M-mediated
hyperthermia were as low as those without NPrCAP/M or
after NPrCAP/M treatment without hyperthermia (Figure 8).
These results suggested that NPrCAP/M-mediated hyperther-
mia induced non-apoptotic cell death or necrosis.
DISCUSSION
The temperature at the center of the pellet of NPrCAP/M-
treated B16F1 cells rose to over 501C within 10minutes; thus,
the NPrCAP/M was a good heat generator, comparable to
MCL or 4-S-CAP-loaded magnetite (Shinkai et al., 1996;
Table 1. Presence of iron-containing tumor cells in
mice injected with NPrCAP/M or magnetite
Number of mice bearing a Berlin-blue positive
tumor/number of total mice tested
B16F1 EG7 RMA
Exp I NPrCAP/M 5/5 0/5 NT
Exp II NPrCAP/M 3/4 NT 0/4
Exp III NPrCAP/M 3/5 0/5 NT
Exp IV magnetite 0/3 0/3 NT
Exp V magnetite 0/3 NT 0/3
Mice bearing B16F1 melanoma and EG7 or RMA lymphoma on the left
and right flanks, respectively, were intraperitoneally given NPrCAP/M or
magnetite. Tumors were excised and the presence of iron was examined
by Berlin-blue staining.
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Figure 5. NPrCAP/M plus AMF treatment degraded melanoma cells more significantly than NPrCAP/M without the AMF. After cells were cultured in the
NPrCAP/M-containing medium and collected, cell pellets were exposed to sham (’) or AMF (&) irradiation. Treated cells were collected and the number of
viable cells not stained by trypan blue was counted. Data and bars are mean±SD of three independent experiments (*Po0.05). (a and b) show results for
melanoma and non-melanoma cell lines, respectively.
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Yanase et al., 1997; Ito et al., 2007). To examine NPrCAP/M
as a tyrosinase substrate, we could not use the spectro-
photometric assay owing to the brown suspension of the
substrate. Thus, we used a method based on the fact that
ortho-quinone obtained from tyrosinase oxidation of the
substrate can be trapped with cysteine, and we monitored the
cysteine adduct with HPLC. Tandon et al. (1998) have
reported that NPrCAP is a very good substrate for tyrosinase
and the enzyme’s kinetic parameters (Km and Vmax) were
found to be similar to those of the homolog N-acetyl-4-S-
CAP. They also reported that the Km values for 4-S-CAP and
NPrCAP were 117 and 340 mM, whereas the Vmax values were
39.0 and 5.4 mmolmin1 mg1 of protein, respectively. In this
study, the ratio of 4-S-CAP to NPrCAP/M in the reaction
velocity on tyrosine oxidation was 16. The reaction velocity
was not as good as for 4-S-CAP (Figure 2). However, it should
be efficient enough, if we consider the bulky structure of
NPrCAP/M.
Pigmented melanoma cells, such as B16F1, MM418, 70W,
and SK-mel-23, captured larger amounts of iron from
NPrCAP/M than from magnetite (Figure 3). These pigmented
melanoma cells also captured magnetite particles without
NPrCAP, although the amount of iron from the magnetite was
lower than that from NPrCAP/M. It is unclear why non-
pigmented AK-1 and 96E and non-melanoma HeLa cells
incorporated NPrCAP/M more efficiently than magnetite.
It is possible that an unidentified receptor for cysteaminyl-
phenols might be present on the surface or in the cytoplasm
of the cells. When mice bearing B16F1 melanoma were
intraperitoneally injected with NPrCAP/M, a total of 11 of 14
melanoma tissues on 14 mice contained B16F1 cells showing
Berlin blue iron staining. As NPrCAP/M was injected into the
peritoneal cavity in the mice, the nanoparticles were
delivered to the B16 melanoma in the subcutis through the
bloodstream. In the B16F1 tumors in the mice injected with
magnetite, blue-stained cells were detected in the encapsu-
lating fibroblast-like cells, but not in the tumor cells,
suggesting that NPrCAP/M, but not magnetite, was preferen-
tially delivered to the B16F1 cells. However, a large part of
NPrCAP/M given i.p. was captured in reticuloendothelial cell
systems such as the liver and spleen in the mice (data not
shown). Clinical trials using the present magnetite-NPrCAP
nanoparticles might be limited to lesional therapy against
melanoma. We have proceeded to a phase I/II study of the
effect of NPrCAP/M-mediated hyperthermia not only on
treated tumors but also on non-treated metastatic tumors.
Hyperthermia reduces cell viability and proliferation in
a time- and temperature-dependent manner in melanoma
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Figure 6. Tumor volumes of the B16F1-bearing mice treated by magnetite-
and NPrCAP/M-mediated hyperthermia. (a) Comparison of groups in the first
19 days after tumor transplantation. Magnetite or NPrCAP/M (4mg of
magnetite or its equivalent) was injected directly into subcutaneous B16F1
tumors, which were then irradiated with an AMF at 461C for 30minutes. Each
point represents the mean±SD of five mice. All data are presented as
mean±SD. (b) Comparison of tumor volumes in each group on the 19th day.
*Po0.005, tumors treated by NPrCAP/M with the AMF, magnetite (M) with
the AMF, and NPrCAP/M without the AMF were significantly different from
those of control mice.
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Figure 7. The sub-G1 fraction was not observed in NPrCAP/M-treated and
AMF exposed cells. After cells were treated with NPrCAP/M followed by AMF
irradiation and culture for 24 or 48 hours, adherent and floating cells were
collected and sub-G1, G1, S, and G2/M populations were quantified with a
FACScan Cell Sorter. (a): SK-mel-23 with Ad-LacZ, (b): B16F1 with LacZ, (c):
SK-mel-23 with Ad-p630, (d): B16F1 with Ad-p630, (e): SK-mel-23 with
NPrCAP/Mþ AMF, (f): B16F1 with NPrCAP/MþAMF.
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cells (Shellman et al., 2007). Intracellular hyperthermia of
NPrCAP/M-treated cells resulted in a significant degradation
of melanoma cells (Figure 5a). No difference was found in the
cell numbers of non-melanoma cell lines between NPrCAP/
M- and magnetite-treated dishes (Figure 5b). These results
were comparable to those of an iron-incorporation assay of
cells cultured in NPrCAP/M- and magnetite-containing media
(Figure 3), suggesting that the targeting ability of NPrCAP/M
to melanocytic cells determined the degree of cell degrada-
tion. In a previous study, significantly higher therapeutic
effects were observed in mice treated with 4-S-CAP/
MCLþAML (431C) than in those treated with 4-S-CAP/MCL
or hyperthermia alone (Ito et al., 2007). In our animal-model
experiments, growth of transplanted B16F1 tumors was
suppressed more effectively than in the untreated control.
Because untreated control mice died on the 19th and 21st
days after inoculation, survival curves over a period of 60
days could not be compared. However, two and one mice
that received NPrCAP/M- and magnetite-mediated hyper-
thermia survived to the 60th day after treatment, respectively,
whereas mice belonging to the other groups did not.
Therefore, NPrCAP/M- and magnetite-mediated hyperther-
mia was suggested to be more effective for tumor suppression
than treatment without heat. Interestingly, NPrCAP/M injec-
tion without heat suppressed B16 melanoma more than in the
control mice (Figure 6b), suggesting that NPrCAP possessed
intrinsic cytotoxicity against melanoma cells. Another experi-
mental system that can evaluate targeting, permeating, and
suppressive abilities of NPrCAP/M needs to be designed.
Necrotic, but not apoptotic, cell death is believed to
induce inflammation and immunity in the host (Shellman
et al., 2007). When HL-60 cells were cultured at 431C for
1 hour, cell degradation was observed in association with
cellular DNA fragmentation and activation of caspases 3 and
8 (Han et al., 2007). It has also been reported that
hyperthermia at 41–441C promotes TRAIL-induced apoptosis
by facilitating caspase activity, whereas hyperthermia at
45–461C inhibits this type of apoptosis (Yoo and Lee, 2007).
In contrast to in vivo observation of apoptotic cell death of
follicular melanocytes in NPrCAP-injected mice (Minamitsuji
et al., 1999), we found no evidence of apoptosis in cells
treated with NPrCAP/M-mediated hyperthermia at 431C.
None of the caspase 8, caspase 9, or caspase 3 required for
the execution of the final phase of apoptosis was activated in
cells treated with NPrCAP/M and irradiated with the AMF.
Although it is unclear why NPrCAP/M-mediated hyper-
thermia at a relatively low temperature (431C) induced non-
apoptotic cell death, this thermotherapy might elicit systemic
T-cell immunity in advanced melanoma. Evidence along this
line has been obtained by our group (Sato et al., manuscript
submitted for publication).
HSPs are molecular chaperones in the cytoplasm upregu-
lated by various stress stimuli that damage proteins
and promote accumulation of misfolded proteins (Brostrom
and Brostrom, 1998). HSP70 was efficiently produced and
excreted from B16F1 cells treated with NPrCAP/M and
heated at 431C compared with those heated at 461C (data
not shown). When transplanted B16F1 melanoma in mice
was treated with NPrCAP/M-mediated hyperthermia at 431C
for 30minutes, rechallenged melanoma was clearly sup-
pressed (Takada et al., manuscript submitted for publication).
In this animal model system, the first tumors treated at 431C
contained larger amounts of HSP70 than those treated at
461C. Judging from these results, HSP70 was produced most
abundantly by the NPrCAP/M-mediated hyperthermia at
431C, and the combination therapy with NPrCAP/M plus
hyperthermia at this temperature resulted in the most
significant therapeutic effect on advanced melanoma.
MATERIALS AND METHODS
Cell lines and cell culture
Human cancer cell lines (T98G, HeLa, SaOS2, HaCaT, H1229, and
CaSki), human melanoma cell lines (SK-mel-23, SK-mel-24, SK-mel-
118, MM418, 70W, TXM18, MMIV, AK-1, and 96E), murine
melanoma cell line B16F1, and fibroblast cell line NIH3T3 were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco
BRL, Gaithersburg, MD) supplemented with 5% fetal bovine serum
(FBS) and antibiotics. Murine lymphoma cell lines EG7, LLC and
RMA were cultured in RPMI-1640 supplemented with 5% FBS.
Primary human epidermal melanocytes (BioWhittaker Inc., Walker-
ville, MD, USA) were grown in the basal medium supplemented
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Figure 8. Caspases 3, 8, and 9 were not activated in cells that received
NPrCAP/M-mediated hyperthermia. B16F1 mouse melanoma cells and SK-
mel-23 human melanoma cells were treated with NPrCAP/M with or without
hyperthermia. Cells were infected with 20 pfu per cell of Ad-p630 or Ad-LacZ
for 24 hours for the positive control of apoptotic cell death. Cells were
collected and processed for assay of caspase activities. Error bars represent the
mean±SD from two separate experiments.
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with basic FGF, hydrocortisone, TPA, insulin, and bovine pituitary
extract according to the manufacturer’s instructions.
Establishment of tumors in mice
Female C57BL/6 mice (age 4 weeks, weighing approximately 10.0 g)
were purchased from Hokudo Co. Ltd. (Sapporo, Japan). Cell
suspensions containing approximately 1 106 B16F1 melanoma,
EG7, or RMA lymphoma cells in 0.1ml of phosphate-buffered saline
(PBS) were injected subcutaneously into C57BL/6 mice after
anesthesia by diethyl ether. B16F1 melanoma and EG7 or RMA
lymphoma cells were injected subcutaneously into the left and right
flanks of C57BL/6 mice, respectively. Mice with tumors received
intraperitoneal administration of 123.8mg of NPrCAP/M on the third
day after tumor injection. At the 15th day after transplantation,
tumors were removed and processed for Fe staining. The Committees
for Animal Research of Sapporo Medical University approved the
experimental protocols of this research project.
Animal treatment model
Mouse B16F1 melanoma cells (5.0 105) in 0.1ml of PBS were
inoculated s.c. into the right flanks of 4-week-old female C57BL/6
mice. On day 5 after inoculation, mice were randomly divided into
control and treatment groups. Each group was composed of five
mice. With a 26-G microsyringe, the B16F1 melanoma-bearing mice
were injected with 0.1ml of NPrCAP/M or magnetite (40.0mgml1
solution) directly into the tumor site in a single-dose administration
on days 5, 7, and 9. Hyperthermia was carried out on days 6, 8, and
10; mice were exposed to the AMF inside the coil and heated at
461C for 30minutes. Temperatures on the tumor surface were
measured using an optical fiber probe (FX-9020; Anritsu Meter,
Tokyo, Japan). Tumor size was measured every other day for 60 days
by the formula: long axis (short axis)2 0.5. Data were analyzed
by one- or two-way analysis of variance, and then differences in
experimental results for tumor growth were assessed by Sheffe’s test
to compare all the experimental groups, or by Dunnett’s test, which
compared the experimental versus the control groups.
Iron oxide and chemicals
Magnetite nanoparticles (Fe3O4; average particle size, 10 nm) were
kindly provided by Toda Kogyo (Hiroshima, Japan). 4-S-CAP was
prepared as described by Padgette et al. N-succinimidyl-3-[2-
pyridyldithio] propionate and mushroom tyrosinase (6050Umg1)
were obtained from Molecular Biosciences, Inc. (Boulder, CO) and
Sigma Chemical Co. (St Louis, MO), respectively. 3-Aminopropyl-
triethoxysilane and N-[g-maleimidobutyryloxy]sulfosuccinimide es-
ter were products of Tokyo Chemical Industry (Tokyo, Japan) and
Pierce (Rockford, IL), respectively. All other chemicals were of
analytical grade.
Synthesis of N-(1-mercaptopropionyl)-4-S-cysteaminylphenol
(NPrCAP-SH)
A mixture of 1.81 g of 4-S-CAP (10.7mmol) and 4.13 g of N-
succinimidyl-3-[2-pyridyldithio] propionate (13.2mmol) in 5ml of
pyridine was stirred for 2 hours at room temperature. After
evaporation, the residue was purified by silica gel column
chromatography (ethyl acetate:n-hexane; 2:1 v/v as eluant) to give
a disulfide (3.70 g; 94%). Then 4.29 g of dithiothreitol (27.5mmol)
was added to a stirred solution of the disulfide (3.70 g; 10.3mmol) in
5ml of methanol at room temperature. After 2 hours the mixture was
evaporated and the oily residue was purified by silica gel column
chromatography (ethyl acetate:n-hexane; 2:1 v/v) to give 2.19 g of
NPrCAP-SH (80%) as a colorless crystal after recrystallization (ethyl
acetate ether). The elemental analysis of NPrCAP-SH was as follows:
Anal. Calcd for C11H15N1O2S2: C, 51.36; H, 5.84; N, 5.45; S, 24.90;
Found: C, 51.41; H, 5.78: N, 5.50; S, 24.83. The resulting material
was subjected to liquid chromatography/mass spectrometry/mass
spectrometry (LC/MS/MS) analysis using an electrospray ionization/
ion trap mass spectrometer (LCQ Deca XP, Thermoelectron, Tokyo,
Japan). The analysis was carried out directly by MS/MS at a positive
charge; [MþH]þ : m/z 258, 164, 153, 132, 125. 1H NMR was
measured at 400MHz (CD3COCD3): 2.45 p.p.m. (2H, t, J¼ 6.8Hz),
2.71 p.p.m. (2H, m), 2.88 p.p.m. (2H, t, J¼ 6.3Hz), 3.32 p.p.m. (2H,
m), 6.68 p.p.m. (2H, d, J¼ 8.0Hz), 7.31 p.p.m. (2H, d, J¼ 8.0Hz).
Conjugation of NPrCAP-SH with magnetite
To prepare the aminosilane-coated magnetite nanoparticles, 10ml
(concentration, 40mgml1) of magnetite nanoparticles and 0.1ml of
3-aminopropyltriethoxysilane were mixed and incubated for 1 hour
with stirring at room temperature. The resultant magnetic suspension
was then washed three times with 10mM phosphate buffer (pH 6.8)
by centrifugation at 2,500 r.p.m. for 2minutes and resuspended in
10ml of phosphate buffer. For conjugation of maleimide cross-
linkers, the magnetite suspension was mixed with 200ml of N-[g-
maleimidobutyryloxy]sulfosuccinimide ester (10mgml1), and in-
cubated in PBS for 30minutes with shaking at room temperature.
The resultant magnetite suspension was washed three times with
water by centrifugation at 2,500 r.p.m. for 2minutes. Then 0.5ml of
NPrCAP-SH (50.0mgml1 of ethanol) was added to 10ml of the
magnetite suspension (40.0mgml1) and the mixture was stirred for
30minutes at room temperature. After standing for 2 hours at room
temperature, the suspension was washed twice with water by
centrifugation at 3,000 r.p.m. for 1minute. The resultant NPrCAP/M
was resuspended in Milli-Q water to a concentration of 40mgml1.
Analysis of NPrCAP incorporated with magnetite nanoparticles
The degree of incorporation of NPrCAP-SH with magnetite was
determined by hydrolysis with 6M HCl followed by HPLC analysis of
the resultant 4-S-CAP. Briefly, the amount of 4-S-CAP produced by
the hydrolysis of NPrCAP/M with 6M HCl at 1101C for 1.5 hours was
measured by HPLC using a Jasco PU-980 Intelligent liquid
chromatogram with a Jasco 851-AS Intelligent autosampler (JASCO,
Tokyo, Japan), a Jasco 875-UV/VIS detector, and Shiseido C18
reverse-phase column (Capcell Pak C18, 4.6 250mm; 5.0 mm
particle size). The UV detector was set at 250 nm. The mobile phase
used was methanol:H2O:1.0 M HClO4, 10:90:1.5 by volume. The
analyses were performed at 501C at a flow rate of 0.7mlminute1.
The concentration of iron, which formed a red complex with
thiocyanate, was quantitated by absorbance at 480 nm (Owen and
Sykes, 1984).
Tyrosinase oxidation of NPrCAP/M
Mushroom tyrosinase (80 mg) was added to a reaction mixture
containing 100mM NPrCAP/M and 200mM cysteine in 1ml of 50mM
sodium phosphate buffer (pH 6.8), and oxidation was carried out at
371C. At 30minutes, 1 hour, and 3 hours, a 100-ml aliquot of the
reaction mixture was removed and mixed with 900ml of 0.4 M
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HClO4. The concentrations of the substrate remaining as 4-S-CAP
and 5-S-cysteaminyl-3-S0-cysteinylcatechol produced were mea-
sured by hydrolysis with 6M HCl followed by HPLC analysis (see
above section, Analysis of NPrCAP incorporated with magnetic
particles). The retention times of 4-S-CAP and 5-S-cysteaminyl-3-S0-
cysteinylcatechol were 14.4 and 7.9minutes, respectively.
Measurement of iron in the NPrCAP/M-exposed cells
Subconfluently growing melanoma and non-melanoma cells
(8 104 cm2) in a 25 cm2 flask were refed with the medium
containing 5.94mg of NPrCAP/M or magnetite (84 mgml1). To
discriminate between incorporation of NPrCAP/M by direct attach-
ment to cells and that by diffusion from the medium, culture flasks
were fixed on a slanted disc (601) and rotated slowly for 30minutes.
After the cells were washed with PBS twice and collected, they were
dissolved completely in 200ml of concentrated HCl and incubated at
431C for 30minutes. Then, 10 ml of H2O2 and 4ml of 1% potassium
thiocyanate were added in sequence to the cell solution. The iron
concentration of magnetite nanoparticles was measured using the
potassium thiocyanate method as described above.
Cytotoxicity of NPrCAP/M in combination with AMF irradiation
For cytotoxicity measurement, 5 106 B16F1, MM418, SK-mel-23,
TXM18, H1229, HaCaT, HeLa, and SaOS2 cells were cultured in the
medium containing 5.94mg of NPrCAP/M or magnetite
(1.19mgml1) for 20minutes. Then, the cells were harvested by
centrifugation at 400 g for 10minutes and the cell pellets were
subjected to AMF irradiation at 431C for 30minutes. The AMF was
generated by using a horizontal coil (inner diameter 7 cm, length
7 cm) with a transistor inverter (LTD-100-05; Dai-ichi High
Frequency Co., Tokyo). The magnetic field frequency and intensity
were 118 kHz and 30.6 kA/M (384Oe), respectively. Cell tempera-
tures were measured and monitored using an optical fiber probe
(Anritsu Meter, Tokyo, Japan). After AMF irradiation, aliquots (1/10)
of cells were seeded in a dish and cultured for a further 48 hours.
Viable cells were counted using a hemocytometer.
Recombinant adenoviruses
Propagation, plaque formation, and inoculation of recombinant
adenoviruses were described elsewhere (Yamano et al., 1999). Ad-
LacZ is a replication-deficient recombinant adenovirus carrying b-
galactosidase. Ad-p630 is a recombinant adenovirus expressing
modified p63, which was provided by T Tokino (manuscript in
preparation and personal communication). The construction of the
original adenovirus Ad-p63 containing the human p63 gene was
described previously (Sasaki et al., 2001, 2003). Cells were infected
with 20 plaque-forming units of a recombinant adenovirus,
incubated for 60minutes at 371C, and cultured in fresh DMEM with
5% FBS for 48 hours before flow cytometric analysis or caspase
assay.
Flow cytometric analysis
After B16F1 and SK-mel-23 cells were cultured in the NPrCAP/M-
containing medium (4.6mgml1) for 30minutes, they were sub-
jected to AMF irradiation at 431C for 30minutes, reseeded in the
medium, and cultured for 24 hours. Then adherent and floating cells
were collected together and washed in ice-cold PBS. The cells were
dehydrated in 75% cold ethanol and stored on ice for 2 hours. Then
they were rehydrated in cold PBS and incubated in the presence of
RNaseA (50 mgml1) (Sigma Aldrich Japan, Tokyo, Japan) at 371C for
30minutes. After incubation, the cells were rinsed twice in ice-cold
PBS and suspended in 2.0ml of PBS containing 50 mgml1
propidium iodide (Sigma Aldrich Japan) at 41C for 2 hours. Cell
debris and fixation artifacts were gated out, and sub-G1, G1, S, and
G2/M populations were quantified with a FACScan Cell Sorter
(Nippon Becton Dickinson, Tokyo, Japan) using the CELL QUEST
program.
Caspase enzyme assay
After 5 106 B16F1 and SK-mel-23 cells were collected in 15ml
tubes, 5.94mg of NPrCAP/M was separately added to the cell
pellets, which were then incubated for 20minutes at 371C in a CO2
incubator. Cells were harvested by centrifugation at 400 g for
10minutes and irradiated by the AMF as described above. Cells
were then collected and seeded in 10 cm dishes and cultured for a
further 24 hours. Both the floating and the adherent cells were
collected, washed with PBS, and processed for caspase assay.
Activities of caspases 3, 8, and 9 were measured using a colorimetric
protease kit according to the manufacturer’s protocol (MBL, Nagoya,
Japan).
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